

(HMIS Form 105) Health Unit Outpatient Monthly Report

Health Unit Name:	Level:	CODE
HSD:		
District:		
Financial Year:		



DESCRIPTION AND INSTRUCTIONS

Objective: To report the monthly data for OPD attendances, diagnoses, MCH, HIV/AIDS service,

Laboratory, stock status of essential drugs and supplies and finances, among others.

Timing: 7th day of the following month

Copies: This report form is in triplicate. The original (white) copy is sent to the District; the

duplicate (pink) copy is sent to the HSD and the triplicate (yellow) copy is retained by the

Health Facility.

For Regional Referral Hospitals and National Referral Hospitals, the original (white) copy is sent to the respective district health office/City Authority for KCCA, and the other copies

should be retained by the facility.

Responsibility: Health Unit In-Charge

PROCEDURE:

1. All health units must compile and submit the HEALTH UNIT OUT-PATIENT MONTHLY REPORT (HMIS 105). The health unit is required to compile the type of report by origin of the population its serves e.g Refugee hosting district they will report a report type for Nationals and for refugees respectively.

Page 1 - 9 contains:

Section 1 with three sub-sections (1.1-OPD ATTENDANCES, 1.2-REFERRALS AND 1.3-OUTPATIENT DIAGNOSES). The values are obtained from tables 1a, 1b, 1c, 1d and 1e (Health Unit Outpatient daily diagnoses). If the district wishes to include additional diseases of local interest, they may do so under the variable of other diagnoses. The DHMT will be responsible for ensuring all the health units in the district are aware of the chosen additional diagnoses.

2 Page 10 - 17 contains:

Section 2, shows a summary of Maternal and Child Health Services, it includes sub-sections (2.1-Antenatal, 2.2-Maternity, 2.3-Postnatal, 2.4-Exposed Infant Diagnosis services, 2.5-Early retention monitoring for EMTCT women, 2.6-Family Planning and 2.7-Child Health Services. The values are obtained from Table 2a (Health Unit Daily Maternal Health Attendance Summary), Table 3a (Health Unit EPI Daily Attendance Summary) and Table 4a (Health Unit Daily Family Planning Summary).

Note: DPT-HepB+Hib vaccine doses wasted = doses accessed – doses administered to children in a given reporting period (in this case a month) where:

- Doses accessed = (Start of month Balance + Total doses received in a month) (End of month balance + Doses given to other Units)
- Doses administered = Total Number of children (under and above 1 year) immunized in a reporting period

For BCG, children above one year receive twice as many doses of vaccine as the under one year olds and therefore total number of doses administered = No of children <1yr immunized + No of children >1yr immunized x 2.





Section 3, shows a summary of Hepatitis B diagnosis and vaccination

3. Page 22 -22 contains:

Section 4: HIV/AIDS testing services. Information is obtained from HTS register, MCH registers, SMC registers and Health Unit B register.

4. Page 23 contains:

Section 5: Safe Male Circumcision. Information is obtained from the Safe Male Circumcision Register.

5. Page 24 – 25 contains

Includes Section 6: Essential Medicines and Health Supplies Stock Status where values are obtained from the Health Facility Stock Book and Stock Cards.

Sub-Section 7, 8 and 9: shows a summary of outreach activities, Meeting and Support supervision activities both planned and actual number carried out, this is obtained from the health facility work plan and outreach records of the Individual units within the health facility.

Note: The storekeeper should also report verbally to the Health Facility In-charge and District/HSD Authorities whenever the stock levels reach minimum stock level.

6. Page 26 - 29 contains:

Section 10: Includes a summary of laboratory tests. The information is obtained from Table 17a (Laboratory Tests Daily Summary) and

Section 11: (Financial summary): The information for the financial summary is obtained from Health Facility Cash Analysis Book.

Section 12: (comments by the health facility in-charge): A copy of the comments should be written in the health unit's LOGBOOK.



			НІ	MIS	10	5: H	EAI	LTH	I UN	III	OU.	ΓI	PATIEN	T M	ON	ITHL	_Y F	REP	OR	Т			Ра	ge 1
Health	n Unit:												Level:							0	Code	.		
Distric	:t:												HSD:											
Sub c	ounty										Re	ep	orting Pe	eriod	: M	onth:					Yea	r:		
Repor	t Type:	Na	ition	al [F	Refu	ıgee				Forei	igne	r $ abla$	7								
-	• •								_					•		_	.	6 E	- C D	TU		40h	ITL	
						•		EK	KAI	_3	ANL	,	DIAGN									/IOI	NIF	1
1.1 0	UTPAT											ı	1.2	2 00		ATIE							201	
Catego	ory	0-2 day	-	29 d - 4	-	5 – 9	eyrs) – Yrs		rs &		Catego	ry		lays		lays Yrs	5 – 9	9Yrs		– Yrs		rs & ove
		M	F	M	F	M	F	M	F	М	F				М	F	M	F	M	F	M	F	М	F
OA01.													OR01.Refe											
OA02.													OR02.Refe											
	ndance	NATU								 - na			rals from u	nit										
1.3	OUT	AIII	ENI	אוט	AGN	051			days				ys - 4Yrs		5 - 9	9Yrs		10	– 19`	Vre	2)Yre	& ah	ove
Diagn							Ma		Fem		Male	_	Female	Ma		Fema	le	Male		emale		lale		male
	Epidemi						1	1					1		ı								1	
aria	EP01a		<u> </u>		ver														_		_			
EP01. Malaria	EP01b					/D /											_							
	EP01c			contir Pos		(B/s																		
EP(EP01c					ited															\top			
EP02.	Acute FI	accid	Para	alysis	;																			
	Animal E					ies)															1			
EP04.	Cholera		<u> </u>																					
EP05.	Dysente	ry																						
EP06.	Guinea	Worm	1																					
EP07.	Measles	;																						
EP08.	Bacteria	l Men	ingiti	is																				
EP09.	Neonata	ıl teta	nus																					
EP10.	Plague																							
EP11.	Yellow F	ever																						
EP12.	Other Vi Fevers	ral Ha	aemo	orrhag	gic																			
EP13.	Severe /	Acute	Res	pirato	ory																\top			
EP14.	Adverse	Even	nts	Seri	ous										\dashv				\top		\top			
	Followin Immuniz (AEFI)	zation		Non	Serie	ous									\dashv									
FP15.	Typhoid	Feve	r					T									T		\top		\top			

EP16. Presumptive MDR TB cases

EP17. Other Emerging infectious Diseases e.g. Influenza like illness (ILI), SARS

CD01. Diarrhoea - Acute CD02. Diarrhoea -Persistent CD03. Urethral discharges CD04. Genital ulcers

1.3.2 Other Infectious / Communicable Diseases



Diamagia	0-28	days	29 day	s - 4Yrs	5 –	9Yrs	10 –	19Yrs	20Yrs	& above
Diagnosis		Female	Male	Female	Male	Female	Male	Female	Male	Female
1.3.2 Other Infectious / Communicable		es (Conti	nued)							
CD05. Sexually Transmitted Infection due to Sexual Gender Based Violence										
CD06. Other Sexually Transmitted Infections										
CD07. Urinary Tract Infections (UTI)										
CD08. Intestinal Worms										
CD09. Haematological Meningitis										
CD10. Other types of meningitis										
CD11.Cough or cold - No pneumonia										
CD12. Pneumonia										
CD13. Severe Pneumonia										
CD14. Skin Diseases										
CD15. Tetanus (over 28 days)										
CD16. Sleeping sickness						ĺ				
CD17. Pelvic Inflammatory Disease (PID)										
CD18. Brucellosis										
1.3.3 Neonatal Diseases										
ND01. Neonatal Sepsis (0-7days)										
ND02. Neonatal Sepsis (8-28days)										
ND03. Neonatal Pneumonia (0-7days)										
ND04. Neonatal Pneumonia(8-28days)										
ND05. Neonatal Meningitis										
ND06. Neonatal Jaundice										
ND07. Premature baby (as a Condition for management)										
ND08. Other Neonatal Conditions										
1.3.4 Non Communicable Diseases/Co	ondition	5								
NC01. Sickle Cell Anaemia										
NC02. Other types of Anaemia										
NC03. Gastro-Intestinal Disorders (non-Infective)										
NC04. Pain Requiring Palliative Care										
1.3.5 Oral diseases										
OD01. Dental Caries										
OD02. Gingivitis										
OD03. HIV-Oral lesions										
OD04. Oral Cancers										
OD05. Other Oral Conditions										
1.3.6 ENT conditions										
EN01. Otitis media acute and chronic										
EN02. Mastoiditis										
EN03. Hearing loss										
EN04. Rhinitis										
EN05. Sinusitis										
EN06. Epixtasis										
EN07. Adenoid Hypertrophy										
EN08. Foreign Body in nose ear and aero- digestive system										
EN09. Infected pre -auricular sinuses and abscess										



Nate Female Male Female Male Female Male Female Male Female Male Female Male Semale Semale			& above
EN10. Otitis external EN11. Mastoid abscess EN12. Vertigo EN13. Tonsillitis EN14. Tonsillar hypertrophy EN15. Tinnitus EN16. Head and neck cancers EN17. Other ENT conditions EO1. Allergic conjunctivitis EC02. Bacterial Conjunctivitis EC03. Ophthalmia neonatorum EC04. Other Forms of Conjunctivitis EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (< 6/60) EC08. Refractive errors EC09. Glaucoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)	Female	Male	Female
EN11. Mastoid abscess EN12. Vertigo EN13. Tonsillitis EN14. Tonsillar hypertrophy EN15. Tinnitus EN16. Head and neck cancers EN17. Other ENT conditions 1.3.7 Eye conditions EC01. Allergic conjunctivitis EC02. Bacterial Conjunctivitis EC03. Ophthalmia neonatorum EC04. Other Forms of Conjunctivitis EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (<6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EN12. Vertigo EN13. Tonsillitis EN14. Tonsillar hypertrophy EN15. Tinnitus EN16. Head and neck cancers EN17. Other ENT conditions 1.3.7 Eye conditions EC01. Allergic conjunctivitis EC02. Bacterial Conjunctivitis EC03. Ophthalmia neonatorum EC04. Other Forms of Conjunctivitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (>6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EN13. Tonsillitis EN14. Tonsillar hypertrophy EN15. Tinnitus EN16. Head and neck cancers EN17. Other ENT conditions 1.3.7 Eye conditions EC01. Allergic conjunctivitis EC02. Bacterial Conjunctivitis EC03. Ophthalmia neonatorum EC04. Other Forms of Conjunctivitis EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (<6/60) EC08. Refractive errors EC09. Glaucoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EN14. Tonsillar hypertrophy EN15. Tinnitus EN16. Head and neck cancers EN17. Other ENT conditions 1.3.7 Eye conditions EC01. Allergic conjunctivitis EC02. Bacterial Conjunctivitis EC03. Ophthalmia neonatorum EC04. Other Forms of Conjunctivitis EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (< 6/60) EC08. Refractive errors EC09. Glaucoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC17. Corneal scars (Non trachomatous)			
EN15. Tinnitus EN16. Head and neck cancers EN17. Other ENT conditions 1.3.7 Eye conditions EC01. Allergic conjunctivitis EC02. Bacterial Conjunctivitis EC03. Ophthalmia neonatorum EC04. Other Forms of Conjunctivitis EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (<6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EN16. Head and neck cancers EN17. Other ENT conditions 1.3.7 Eye conditions EC01. Allergic conjunctivitis EC02. Bacterial Conjunctivitis EC03. Ophthalmia neonatorum EC04. Other Forms of Conjunctivitis EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (< 6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EN17. Other ENT conditions 1.3.7 Eye conditions EC01. Allergic conjunctivitis EC02. Bacterial Conjunctivitis EC03. Ophthalmia neonatorum EC04. Other Forms of Conjunctivitis EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (< 6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
1.3.7 Eye conditions			
EC01. Allergic conjunctivitis EC02. Bacterial Conjunctivitis EC03. Ophthalmia neonatorum EC04. Other Forms of Conjunctivitis EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (< 6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC02. Bacterial Conjunctivitis EC03. Ophthalmia neonatorum EC04. Other Forms of Conjunctivitis EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (< 6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC03. Ophthalmia neonatorum EC04. Other Forms of Conjunctivitis EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (< 6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC04. Other Forms of Conjunctivitis EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (< 6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC05. Corneal Ulcers/ Keratitis EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (< 6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC06. Un Operable Cataract (>6/60) EC07. Operable Cataract (< 6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC07. Operable Cataract (< 6/60) EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC08. Refractive errors EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC09. Glaucoma EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC10. Trachoma EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC11. Vitamin A Deficiency EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC12. Ocular trauma and Burns EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC13. Diabetic Retinopathy (All stages) EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC14. Chorioretinal, Macular & Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
Vitreous Disorders EC15. Uveitis EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC16. Endophthalmitis EC17. Corneal scars (Non trachomatous)			
EC17. Corneal scars (Non trachomatous)			
trachomatous)			
EC18. Tumours			
EC19. Strabismus (All types)			
EC20. Ptosis and other lid Disorders			
EC21. Squamous Cell Carcinoma of Conjunctiva			
EC22. Retinoblastoma			
EC23. Other Malignant Tumours			
EC24. Other Benign Tumours/Growths			
EC25. Other Eye Disorders			
EC26. Blindness			
EC27. Other eye conditions			
EC28. Spectacles Dispensed			
1.3.8 Mental Health			
MH01. Anxiety Disorders			
MH02. Anxiety Disorders due to gender based violence			
MH03. Unipolar Depressive Disorder			
MH04. Bipolar disorder			
MH05. Schizophrenia			
MH06. Post -Traumatic Stress Disorder			
MH07. Epilepsy			
MH08. HIV related psychosis			



Diagnosia	0-28	days	29 day	s - 4Yrs	5 –	9Yrs	10 –	19Yrs	20Yrs	& above
Diagnosis	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
1.3.8 Mental Health (Continued)										
MH09. Alzheimer's disease										
MH10. HIV related dementia										
MH11. Alcohol related Dementia										
MH12. Dementia due to stroke (Diabetes, Hypertension)										
MH13. Other form of Dementia										
MH14. Other Adult Mental Health Conditions										
MH15. Internet addiction										
MH16. Alcohol Use Disorder										
MH17. Substance (Drug) use Disorder										
MH18. Delirium										
MH19. Intellectual disability										
MH20. Autism spectrum disorders										
1.3.9 Neurological Disorders										
NE01. Aphasia or Loss of Language due to Stroke;										
NE02. Dysarthria or Speech Disorder due to Stroke										
NE03. Parkinson's disease										
NE04. Dementia or excessive forgetfulness due to advanced age,										
NE05. Amyotrophic Lateral Sclerosis(ALS)										
NE06. Speech disorders due to Head Injuries(penetrating or closed)										
NE07. Persons in Coma / Emergency Care										
NE08. Alzheimer Disease										
NE09. Down Syndrome (DS)										
NE10. CP / PMLD										
NE11. Child abuse and Neglect										
NE12. Attention Deficit Hyperactivity disorder (ADHD)										
NE13. Learning Disability										
NE14. Conduct disorders										
NE15. Eating disorders (anorexia, Bulimia, other feeding)										
NE16. Somatoform disorders										
NE17. Sleeping Disorders										
NE18. Enuresis/Encopresis										
NE19. Other Childhood Mental Disorders										
NE20. Mental illness due other Medical/ surgical conditions										
NE21. Attempted Suicide/Self-harm										
1.3.10 Chronic respiratory diseases										
CR01. Asthma										
CR02. Chronic Obstructive Pulmonary Disease (COPD)										
1.3.11 Cancers										
CA01. Cervical Cancer										
CA02. Prostate Cancer										
CA03. Breast Cancer										
CA04. Lung Cancer										
CA05. Liver Cancer										



		0-28	days	29 day	s - 4Yrs	5 –	9Yrs	10 –	19Yrs	20Yrs	& above
CA06. Colon Cancer CA07. Kaposis Sarcoma CA08. Other Cancers 1.3.12 Physiotherapy PT01. Muscular disorders. PT02. Joint dysfunction. PT03. Soft tissue injuries. PT04. Chronic respiratory diseases. PT05. Chest trauma/lipiry. PT06. Paralysis due to spinal cord injury and other diseases Injury and other diseases PT07. Cerebral Palsy/Delayder motor or sensory developmental milestones.(CP) PT08. Upper Motor Neuron lesions (UMN) PT09. Facial palsy PT09. Pacial palsy PT10. Lower motor neuron lesions (LMN) PT11. Cynaecological, obstetric and urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neuritis/Route flacoid paralysis PT16. Spine disorders e.g. neck, thoracic, lumber, cocorgeal pains PT17. Cymb nedema. PT18. Patients prescribed with assistive devices PT19. Others T13. Adult Neurological Disorders OT03. Adult Neurological Disorders OT04. Burn injuries OT05. Post-burns contractures OT06. Post-burns contractures OT06. Orthopaedic Conditions OT07. Mental Health Conditions	Diagnosis					Male	Female	Male	Female		Female
CA07. Kaposis Sarcoma CA08. Other Cancers 1.3.12 Physiotherapy PT01. Muscular disorders. PT02. Joint dysfunction. PT03. Soft tissue injuries. PT04. Chronic respiratory diseases. PT05. Chest trauma/Injury. PT06. Paralysis due to spinal cord injury and other diseases PT07. Cerebral Palsy/Delayed motor or sensory developmental milestones (CP) PT08. Upper Motor Neuron lesions (UMN) PT09. Facial palsy PT10. Lover motor neuron lesions (LMN) PT11. Gymaeoological, obstetric and urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT15. Congenital abnormalities PT16. Spine disorders e.g. neck, thoracic, lumber, coccygeal pains PT19. Unber oderma. PT19. Patlents prescribed with assistive devices PT19. Others PT19. Ot	1.3.11 Cancers (Continued)										
CA08. Other Cancers 1.3.12 Physiothorapy PT01. Muscular disorders. PT02. Joint dysfunction. PT03. Soft tissue injuries. PT04. Chronic respiratory diseases. PT05. Chest Tatuman/Injury. PT06. Paralysis due to spinal cord injury and other diseases. PT07. Cerebra Plasly Delayed motor or sensory developmental milestones, (CP) or sensory developmental disorders or sensor developmental disorders or sensor developmental disorders or sensor developmental disorders or sensor developmental Disorders or sensory developmental Disorders or sensory integration disorders or	CA06. Colon Cancer										
1.3.12 Physiotherapy PT01. Muscular disorders. PT02. Joint dysfunction. PT03. Soft tissue injuries. PT04. Chronic respiratory diseases. PT05. Chest trauma/injury. PT06. Paralysis due to spinal cord injury and other diseases. PT07. Cerebral Palsy/Delayed motor or sensory developmental milestones (CP) PT08. Upper Motor Neuron lesions (UMN) PT09. Facial palsy PT10. Lower motor neuron lesions (UMN) PT11. Gynaecological, obstetric and urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neurilisi/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders eg neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT03. Adult Neurological Disorders OT04. Burn injuries OT06. Orthopaedic Conditions OT07. Mental Health Conditions OT07. Mental Health Conditions OT07. Arthrogyyposis OT10. Diabetes OT10. Diabetes OT11. Diabetes OT11. Diabetes OT11. Diabetes OT11. Diabetes OT12. Cancer	CA07. Kaposis Sarcoma										
PT01. Muscular disorders. PT02. Joint dysfunction. PT03. Soft tissue injuries. PT04. Chronic respiratory diseases. PT05. Chest trauma/Injury. PT06. Paralysis due to spinal cord injury and other diseases PT07. Cerebral Palsy/Delayed motor or sensory developmental milestones (CP) PT08. Upper Motor Neuron lesions (UMN) PT09. Facial palsy PT01. Cover motor neuron lesions (UMN) PT09. Facial palsy PT10. Lower motor neuron lesions ((LMN) PT11. Gynaecological, obstetric and urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders e.g neck, thoracic, lumber, occocypeal pains PT17. Lymph cedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT03. Adult Neurological Disorders OT04. Burn injuries OT05. Post-burns contractures OT06. Orthopaedic Conditions OT07. Mental Health Conditions OT07. Mental Health Conditions OT07. Adminipries OT07. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT11. Cancer	CA08. Other Cancers										
PT02. Joint dysfunction. PT03. Soft tissue injuries. PT04. Chronic respiratory diseases. PT05. Chest rauma/Injury. PT06. Paralysis due to spinal cord injury and other diseases injury and other diseases injury and other diseases. PT07. Crebral Palsy/Delayd motor or sensory developmental milestones (CP) PT08. Upper Motor Neuron lesions (LIMN) PT09. Facial palsy PT10. Lower motor neuron lesions (LIMN) PT11. Gynaecological, obstetric and urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders e.g. neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT03. Adult Neurological Disorders OT04. Burn injuries OT05. Post-burns contractures OT06. Orthopaedic Conditions OT07. Mental Health Conditions	1.3.12 Physiotherapy										
PT03. Soft tissue injuries. PT04. Chronic respiratory diseases. PT05. Chest trauma/Injury. PT06. Paralysis due to spinal cord injury and other diseases PT07. Cerebra Palsy/Delayde motor or sensory developmental milestones (CP) PT08. Upper Motor Neuron lesions (UMN) PT09. Facial palsy PT10. Lower motor neuron lesions (LMN) PT11. Gynaecological, obstetric and urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders e.g. neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.313 Occupational therapy conditions OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT03. Adult Neurological Disorders OT04. Burn injuries OT07. Mental Health Conditions	PT01. Muscular disorders.										
PT04. Chronic respiratory diseases. PT05. Chest trauma/Injury. PT06. Paralysis due to spinal cord injury and other diseases PT07. Cerebral Palsy/Delayed motor or sensory developmental milestones (CP) PT08. Upper Motor Neuron lesions (UMN) PT09. Facial palsy PT10. Lower motor neuron lesions (LMN) PT11. Cynaecological, obstetric and urogenital conditions University of the conditions of the	PT02. Joint dysfunction.										
PT05. Chest trauma/Injury. PT06. Paralysis due to spinal cord injury and other diseases PT07. Cerebral Palsy/Delayed motor or sensory developmental milestones, (CP) PT08. Upper Motor Neuron lesions (UMN) PT09. Facial palsy PT10. Lower motor neuron lesions (UMN) PT11. Gynaecological, obstetric and urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders e g neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT03. Adult Neurological Disorders OT04. Burn injuries OT05. Post-burns contractures OT070. Mental Health Conditions OT071. Dibetes OT11. Dibetes OT11. Dibetes OT11. Dibetes OT12. Cancer	PT03. Soft tissue injuries.										
PT06. Paralysis due to spinal cord injury and other diseases injury an	PT04. Chronic respiratory diseases.										
injury and other diseases PT07. Cerebral Palsy/Delayed motor or sensory developmental milestones.(CP) PT08. Upper Motor Neuron lesions (UMN) PT09. Facial palsy PT10. Lower motor neuron lesions (LMN) PT11. Gynaecological, obstetric and urogenital conditions PT12. Amputee	PT05. Chest trauma/Injury.										
or sensory developmental milestones (CP) PT08. Upper Motor Neuron lesions (UMN) PT10. Lower motor neuron lesions (LMN) PT11. Cynaecological, obstetric and urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders e.g neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT04. Burn injuries OT05. Post-burns contractures OT06. Orthopaedic Conditions OT077. Mental Health Conditions OT079. Arthrogryposis OT09. Arthrogryposis OT10. Iniv AIDS OT11. Diabetes OT11. Diabetes OT11. Diabetes OT11. Diabetes	injury and other diseases										
PT09. Facial palsy PT10. Lower motor neuron lesions (LMN) PT11. Gynaecological, obstetric and urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders e.g. neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT03. Adult Neurological Disorders OT04. Burn injuries OT05. Post-burns contractures OT06. Orthopaedic Conditions OT07. Mental Health Conditions OT07. Mental Health Conditions OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT11. Diabetes OT11. Diabetes	PT07. Cerebral Palsy/Delayed motor or sensory developmental milestones.(CP)										
PT10. Lower motor neuron lesions (LMN) PT11. Gynaecological, obstetric and urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders e.g. neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT03. Adult Neurological Disorders OT04. Burn injuries OT05. Post-burns contractures OT06. Orthopædic Conditions OT070. Mental Health Conditions OT070. Mental Health Conditions OT08. Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT11. Diabetes	PT08. Upper Motor Neuron lesions (UMN)										
(LMN) PT11. Gynaecological, obstetric and urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders e.g neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT03. Adult Neurological Disorders OT05. Post-burns contractures OT06. Orthopaedic Conditions OT07. Mental Health Conditions OT07. Mental Health Conditions OT08. Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer											
urogenital conditions PT12. Amputee PT13. Altered Posture and gait. PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders e.g neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT03. Adult Neurological Disorders OT05. Post-burns contractures OT06. Orthopaedic Conditions OT07. Mental Health Conditions OT08. Birth Defects and Trauma OT09. Arthrogryposis OT11. Diabetes OT11. Diabetes OT11. Diabetes OT12. Cancer	(LMN)										
PT13. Altered Posture and gait. PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders e.g neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01.Neuro-developmental Disorders OT02.Sensory Integration disorders OT03.Adult Neurological Disorders OT04.Burn injuries OT05.Post-burns contractures OT06.Orthopaedic Conditions OT07. Mental Health Conditions OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer	urogenital conditions										
PT14. Injection neuritis/Acute flaccid paralysis PT15. Congenital abnormalities PT16. Spine disorders e.g. neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT04. Burn injuries OT05. Post-burns contractures OT06. Orthopaedic Conditions OT07. Mental Health Conditions OT08. Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer											
paralysis PT15. Congenital abnormalities PT16. Spine disorders e.g neck, thoracic, lumber, coccygeal pains lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others I.3.13 Occupational therapy conditions OT01.Neuro-developmental Disorders OT02.Sensory Integration disorders OT03.Adult Neurological Disorders OT04.Burn injuries OT05.Post-burns contractures OT06.Orthopaedic Conditions OT07. Mental Health Conditions OT07. Mental Health Conditions OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT11. Diabetes OT12. Cancer OT12. Cancer											
PT16. Spine disorders e.g neck, thoracic, lumber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01.Neuro-developmental Disorders OT02.Sensory Integration disorders OT03.Adult Neurological Disorders OT04.Burn injuries OT05.Post-burns contractures OT06.Orthopaedic Conditions OT07. Mental Health Conditions OT08.Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer	paralysis										
Lümber, coccygeal pains PT17. Lymph oedema. PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01. Neuro-developmental Disorders OT02. Sensory Integration disorders OT03. Adult Neurological Disorders OT04. Burn injuries OT05. Post-burns contractures OT06. Orthopaedic Conditions OT07. Mental Health Conditions OT08. Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer											
PT18. Patients prescribed with assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01.Neuro-developmental Disorders OT02.Sensory Integration disorders OT03.Adult Neurological Disorders OT04.Burn injuries OT05.Post-burns contractures OT06.Orthopaedic Conditions OT07. Mental Health Conditions OT08.Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer	lumber, coccygeal pains										
assistive devices PT19. Others 1.3.13 Occupational therapy conditions OT01.Neuro-developmental Disorders OT02.Sensory Integration disorders OT03.Adult Neurological Disorders OT04.Burn injuries OT05.Post-burns contractures OT06.Orthopaedic Conditions OT07. Mental Health Conditions OT08.Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer											
1.3.13 Occupational therapy conditions OT01.Neuro-developmental Disorders OT02.Sensory Integration disorders OT03.Adult Neurological Disorders OT04.Burn injuries OT05.Post-burns contractures OT06.Orthopaedic Conditions OT07. Mental Health Conditions OT08.Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer	assistive devices										
OT01.Neuro-developmental Disorders OT02.Sensory Integration disorders OT03.Adult Neurological Disorders OT04.Burn injuries OT05.Post-burns contractures OT06.Orthopaedic Conditions OT07. Mental Health Conditions OT08.Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer	PT19. Others										
OT02.Sensory Integration disorders OT03.Adult Neurological Disorders OT04.Burn injuries OT05.Post-burns contractures OT06.Orthopaedic Conditions OT07. Mental Health Conditions OT08.Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer	1.3.13 Occupational therapy condition	ıs									
OT03.Adult Neurological Disorders OT04.Burn injuries OT05.Post-burns contractures OT06.Orthopaedic Conditions OT07. Mental Health Conditions OT08.Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer	OT01.Neuro-developmental Disorders										
OT04.Burn injuries OT05.Post-burns contractures OT06.Orthopaedic Conditions OT07. Mental Health Conditions OT08.Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer	OT02.Sensory Integration disorders										
OT05.Post-burns contractures 0 OT06.Orthopaedic Conditions 0 OT07. Mental Health Conditions 0 OT08.Birth Defects and Trauma 0 OT09. Arthrogryposis 0 OT10. HIV/ AIDS 0 OT11. Diabetes 0 OT12. Cancer 0	OT03.Adult Neurological Disorders										
OT06.Orthopaedic Conditions OT07. Mental Health Conditions OT08.Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer	OT04.Burn injuries										
OT07. Mental Health Conditions 0708.Birth Defects and Trauma OT09. Arthrogryposis 0709. Arthrogryposis OT10. HIV/ AIDS 0711. Diabetes OT12. Cancer 0712. Cancer	OT05.Post-burns contractures										
OT08.Birth Defects and Trauma OT09. Arthrogryposis OT10. HIV/ AIDS OT11. Diabetes OT12. Cancer OT12. Cancer	OT06.Orthopaedic Conditions										
OT09. Arthrogryposis	OT07. Mental Health Conditions										
OT10. HIV/ AIDS 0T11. Diabetes OT12. Cancer 0T12. Cancer	OT08.Birth Defects and Trauma										
OT11. Diabetes OT12. Cancer	OT09. Arthrogryposis										
OT12. Cancer	OT10. HIV/ AIDS										
	OT11. Diabetes										
OT13. Other chronic conditions	OT12. Cancer										
	OT13. Other chronic conditions										
OT14.Cardiac Conditions	OT14.Cardiac Conditions										
OT15. Patients prescribed with assistive devices	OT15. Patients prescribed with assistive devices										
1.3.14 Speech and Language Therapy											
SL01. Speech and language delay/ disorder											
SL02. Motor speech disorders	SL02. Motor speech disorders										
SL03. Hearing impairments	SL03. Hearing impairments										
SL04. Voice disorders	SL04. Voice disorders										



	0-28	3 days	29 day	s - 4Yrs	5 –	9Yrs	10 –	19Yrs		& above
Diagnosis	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
1.3.14 Speech and Language Therap	y (Contin	nued)	Y					Y	Y	
SL05. Dysfluency /stammering										
SL06. Acquired neurological disorders										
SL07. Cleft lip and palate										
SL08. Others										
1.3.15 Disabilities										
DS01.Individuals with Difficulty in seeing	3									
DS02.Individuals with Albinism										
DS03.Individuals with Difficulty in hearing	9									
DS04.Individuals with Speech Difficulties										
DS05.Individuals with delayed age specific motor development										
DS06.Individuals with Dwarfism										
DS07.Individuals with Difficulty understanding										
DS08.Individuals with Difficulty in remembering										
DS09.Individuals with Difficulty in reading	9									
DS10.Individuals with Difficulty in writing										
DS11.Individuals with Difficulty in self-care	:									
DS12.Individuals with Mentally impairment										
DS13. Individuals with Emotionally impairment										
1. 1.3.16 Cardiovascular diseases CV01. Stroke/ Cardiovascular						l		Ι	Π	
Accident(CVA)										
CV02. Hypertension										
CV03. Heart failure										
CV04. Ischemic Heart Diseases										
CV05. Rheumatic Heart Diseases										
CV06. Chronic Heart Diseases										
CV07. Other Cardiovascular Diseases										
1.3.17 Endocrine and Metabolic Diso	rders			1				1	1	
EM01. Diabetes mellitus										
EM02. Thyroid Disease										
EM03. Other Endocrine and Metabolic Diseases										
1.3.18 Injuries	_						ļ	l	l	
IN01. Jaw injuries										
IN02a. Motor Vehicle	İ									
IN02.Road IN02b, Motor Cycle										
Iraffic INO2e Biovelee	1									
Injuries IN02C. Bicycles IN02d. Others	1									
IN03. Injuries due to Gender based violence										
IN04. Injuries (Trauma due to other causes)										
IN05. Animal IN05a. Domestic	1									
bites IN05b. Wild										
IN06. Snake bites										
IN07. Insect bites										
1.3.19 Minor Operations in OPD										
MN01. Tooth extractions										
-	_									
MN02. Dental Fillings										



										RY OF HEALTH
Diagnosis	Male	days Female	29 day Male	rs - 4Yrs Female	5 – Male	9Yrs Female	10 – Male	19Yrs Female	20Yrs Male	& above Female
1.3.20 Neglected Tropical Diseases (N		<u> </u>	IVIAIC	I emale	Wate	I emale	IVIAIC	<u> I emale</u>	IVIAIC	I emale
NT01. Leishmaniasis										
NT02. Lymphatic Filariasis (hydrocele)	1									
NT03. Lymphatic Filariasis (Lympoedema)										
NT04. Urinary Schistosomiasis	 									
NT05. Intestinal Schistosomiasis										
NT06. Onchocerciasis	†									
1.3.21 Maternal conditions										
MC01. Abortions due to Gender-Based Violence (GBV)										
MC02. Abortions due to other causes										
MC03. Number of Post Abortion women who received FP										
MC04. Malaria in pregnancy										
MC05. High blood pressure in pregnancy										
pressure in pregnancy										
MC06. Obstructed labour										
MC07. Puerperal sepsis										
MC08. Haemorrhage related to pregnancy (APH)										
MC09. Haemorrhage related to pregnancy (PPH)										
Total Screened										
MC10. Breast cancer Number with breast cancer										
Total Screened										
MC11. Cervical Number with cervical										
1.3.22 Other OPD conditions										
OP01. All others	Т			1						
Discoso codo1	 									
OP02. Other diagnoses (specify priority Disease code2	+									
diseases for District)	 									
DT01. Deaths in OPD										
1.3.23 Risky Behaviours				1						
RB01. Alcohol use										
RB02. Tobacco use										
RB03. Tobacco exposure										
1.3.24 Emergency Medical Services				,						
ES01. Number of emergency cases at the facility										
ES02. Patients that receive care at the scene of emergency										
ES03. Emergency cases that arrive at the facility using an Ambulance										
ES04. Number of patients assessed for level of consciousness using GCS/ other comma score										
ES05. Number of patients accessing care within 1hr in an emergency unit										
ES06. Number of patients who develop complications within 24 hours after management/care										
ES07. Number of patients with hypoxemia administered with oxygen										
ES08. Number of patients with external haemorrhages controlled										

Page 8

MINISTRY OF HEALT

Diagnosis			0-28 (- 4Yrs			– 9Yrs	5		10 –			20	Yrs 8	& abo	ove
				Fema	le	Male	F	emal	e	Male	Fer	nale	M	ale	Fe	male	M	ale	Fem	ale
		lical Services (C	Continued)																
	ES09a. I e	Medical mergencies																		
		Obstetrics gynaecology emergencies																		
Number of	ES09c. F	Paediatric emergencies			T		T				Т									
death at emergency unit	ES09d.	Surgical emergencies																		
		Road traffic Injuries																		
	ES09f. I	Burns			_								<u> </u>							
		Poisoning			_		\perp				_									
ES10. Total nur Emerger	nber of E ncy Unit	Death in																		
ES11. Number	<u> </u>	ES11a.Tetanus																		\neg
Patients receiving	ا ر	ES11b. Rabies																		
vaccinat	ion for	ES11c. Others																		
1.4 Tuberculos	is and L	eprosy services	\$																	
				<5 y	_		_	- 9yea	_	-	10-14	`		_	_	ears	_	0+ ye		
				Male) F	emal	e M	ale	Fen	nale	Male	Fer	nale	Mal	е	Fema	le M	lale	Fen	nale
TB Screening i					4		+										4			
TP01. Number s			: -! 4: : :!		_		\bot					╀		_			_			
from OPI	D .	nptive TB cases nptive cases diag			_		+								_		_		_	\Box
with TB f	rom OPE				_		\perp			_		$oxed{oxed}$					\perp			
	v and rel	apse TB cases re	egistered		+		+			_							+		H	
in TB trea																				
		cts of TB patients	started				Т			┪							Т		Т	
TP06. Number	of ART cl	lients started on	TPT				T			\neg							Ť			\neg
Leprosy service	es																			
TP07. New and	relapse	PB (Paucibacil	lary)		\Box		Т													
leprosy cases re		MB (MultiBacill	ary)																	
1.5 Nutrition Se	rvices																			
	Data E	lements		0- Mon		6-2 Mon		24- Mon		5- Yea	-9		0-19 ears			20-24 Years			25+ Years	
				M	F	M	F	M	F	M	F	м	F		М	F		М	F	
													<u></u>) t		اپا	3 / E		ų.) t
													Non Pregnant	Pregnant / Lactating		Non Pregnant	Pregnant / Lactating		Non Pregnant	Pregnant / Lactating
		NA01a. MUAC	Таре								П									
NA01. No. of cli who received nutrition assess		NA01b. W/H or L	Z-Score																	
this month	inone in	NA01c. BMI for Z-Score	Age																	
lusing;		NA01e. Body M Index (BMI)	lass																	
NA02. No. of ch ≤-2 SD)	ildren th	at are underweig	ht (W/A																	
NA03. No. of identified malnourished clients this month;	MU (ch MU	A03a. MAM using I JAC: ≥ 11.5cm & < nildren 0-59 mths) JAC: ≥ 19.0cm & < LW 10-25+ yrs)	< 12.5cm																	



	100. 1	TEACHT ONLY OUT A													ye ·		MINISTRY	OF HEALTH	
			M	F	M	F	M	F	M	F	M	F		M	F		М	F	ıt Jg
												Non Pregnant	Pregnant /Lactating		Non Pregnant	Pregnant /Lactating		Non Pregnant	Pregnant /Lactating
1.5 Nutrition	Sorvice	es (Continued)										žā	<u>4</u> – ,		Σď	<u>P</u> //		Σď	<u>7</u>
1.5 Nutrition	Service	NA03b. MAM using W/H or L				Г	Π			Г									
		W/H or L: ≥ -3 SD & < -2 SD																	
		NA03c. SAM using MUAC MUAC: < 11.5cm (children 0-59 mths) MUAC: <19.0cm (PLW 10-25+ yrs)																	
		NA03d. SAM using W/H or L W/H or L: < -3 SD																	
NA03. No. o	f	NA03e. SAM With Oedema																	
identified malnourishe	d	NA03f. Moderately Malnourished																	
clients this month;		(5-9yrs & 10-19yrs: <- 2SD & ≥-3SD;																	
uno monui,		>19yrs: ≥16.0 & ≤16.9)																	
		NA03g. Severely Malnourished (5-9yr & 10-19 yrs: < -3SD;>19yrs: < 16.0)																	
		NA03h. Overweight (5-9yrs: >+1SD & ≤+3SD; >19yrs: ≥25.0 & ≤29.9)																	
		NA03i. Obese (5-9yrs & 10- 19yrs: <+ 2SD; >19yrs: ≥ 30.0)																	
NA04. No. o		NA04a. Total																	
admissions i OTC this mo		NA04b. New Admissions																	
NA05. No. of Readmission		NA05a. Relapses																	
OTC this mor		NA05b. Defaulters																	
NA06. No. of admissions in		NA06a. Total																	
Supplementar Feeding Care	ry (SFC);	NA06b. New Admissions																	
NA07. No. of Readmissions	e in	NA07a. Relapses																	
SFC this Mon		NA07b. Defaulters																	
		NA08a. Discharged as cured within this month																	
NA08. No. o clients with SAM	f	NA08b. Did not respond to care in OTC (non-response) after 3 months of treatment																	
admitted into treatment an		NA08c. Defaulted from care within this month (absent for 2 consecutive visits)																	
		NA08d. Died during treatment within this month																	
		of days spent in OTC for all cured this month																	
NA10. No.	NA10a.E	Discharged as cured within this month																	
of clients with MAM admitted		Did not respond to care in on-response) after 3 months of ent																	
into treatment		Defaulted from care within this month for 2 consecutive visits)																	
and	NA10d. this mo	Died during treatment within nth																	
		of days spent in SFC for all cured this month																	
NA12. No. c		ourished clients who are																	
μυδιι	IAC IOI I	ט				<u> </u>				<u> </u>			Pr	int V	l ersio	n Se	nten	her	2019





2.0 MATERNAL AND CHIL	D HEAL	TH SERVICES	
2.1 ANTENATAL			NUMBER
		Below 15 years	
		15-19 years	
AN01.ANC 1st contacts/	Total	20-24 years	
visits for women		25-49 years	
		50+ years	
	No. in 1	st Trimester	
	Below 1	l5 years	
	15-19 y	ears	
AN02.ANC 4th contacts/ visits for women	20-24 y	ears	
visits for women	25-49 y	ears	
	50+ yea	ars	
		I5 years	
	15-19 y		
AN03. ANC 4+ contacts/	20-24 y		
visits for Women	25-49 y		
	50+ yea		
		15 years	
	15-19 y		
AN04. ANC 8 contacts/	<u> </u>		
visits for Women	20-24 y		
	25-49 y		
	50+ yea		
		15 years	
AN05. Total ANC contacts/	15-19 y		
visits (new clients + Re- attendances)	20-24 y		
	25-49 y		
	50+ yea	ars	
AN06. Referrals to ANC	Total re	ferrals	
unit	From co	mmunity services	
AN07. ANC Referrals from	Total re	ferrals	
unit		others newly	
		in MCH groups 15 years	
		-	
AN08. First dose IPT	15-19 y		
(IPT1)	20-24 y		
	25-49 y		
	50+ yea		
		15 years	
AN09. Second dose IPT	15-19 y		
(IPT2)	20-24 y		
	25-49 y		
	50+ yea		
	Below 1		
ANIAO This L.L. IDT	15-19 y		
AN10.Third dose IPT	20-24 y		
(IPT3)			
(IF 13)	25-49 y	ears	

				MIN	MINISTRY OF HEALTH			
2.1 ANTENATAL (Co	ntinue	d)		NUMBER				
	I	Belo	w 15 ye	ars				
	[·	15-1	9 years					
AN11. IPT 4 & 4+ Dos	se [2	20-2	4 years					
	[2	25-4	9 years					
	!	50+	years					
		Scre	ened for	r TB				
AN12. TB Screening ANC clients	for	Pres	sumed to	have TB				
ANC clients	Ī	Diag	nosed w	vith TB				
			Total					
AN13. Blood & Rhesus	s group ((O)	Rhesus	O+	1.1			
			Total		1-1			
AN14. Blood & Rhesus	s group ((A)	Rhesus	A+				
			Total		1-1			
AN15. Blood & Rhesus	s group ((B)	Rhesus	B+				
AN16. Blood & Rhesu	s droup		Total					
(AB)	o group		Rhesus	AB+				
AN17.No. of pregnan Anaemia using Hb Te								
AN18. No. of pregna (Hb <10g/dl) at ANC	nt wom	en v	vith Anae					
AN19. No. of pregnar anaemia using Hb tes				tested for				
anaemia using Hb tes AN20. No. of pregnar								
(Hb <10g/dl) at ANC				ıılla				
AN21. Pregnant Wom Folic Acid and Iron Su	lphate a	ıt AÑ	IC 1st co	ntact / visit				
(Only Folic Acid recom				· · · · · · · · · · · · · · · · · · ·				
AN22. Pregnant Won of Folic Acid and Iron weeks of gestation								
AN23. Pregnant Wome	en receiv	vina	LLINs at	ANC 1st visit				
AN24. No. of pregna		Ŭ	Total U/					
who received obstetr	ic-ultra		No. don	e before 24				
sound scan during a visit in the reporting i	ny ANC month		weeks of	of gestation				
AN25. No. of pregna		en	Total	-11				
dewormed or receiving			After 28	weeks of				
mebendazole			gestatio	n				
AN26. Pregnant Wortested for syphilis for	nen	t	No. Tes					
time in this pregnanc	y Sy	L	No. Tes No. star	ted Positive				
				treatment				
			No. Tes					
AN27. Male partners syphilis	tested	for		ted Positive				
-76			No. star svphilis	ted on treatment				
			No. Tes					
AN28. Pregnant won	nen test	ted	No. Tes	ted Positive				
for Hepatitis B.				ted on Hep				
				nent Total Number	ANC1			
	nant Below 1				-			
AN29. Pregnant				Number	ANC1			
tested for HIV in	nen newly 15-19 ye ed for HIV in							
this pregnancy at	yea		ANC1					
any ANC visit (TR	yea	rs	Number	ANC1				
& TRR)	50+ ye	ars		Number	ANC1			
					ANC1			





2.1 ANTENATAL (Co	ntinu	ed)	NUMBE	R
			Total Number	ANC1
	Belo	w 15 years	Number	ANC1
AN30. Pregnant Women tested HIV+	15-1	9 years	Number	ANC1
for 1st time this preg-	20-2	4 years	Number	ANC1
nancy (TRR) at any ANC Visit	25-4	25-49 years		ANC1
	50+	years	Number	ANC1
	Belo	w 15 years	Number	ANC1
AN31. HIV+ Pregnant	15-1	9 years	Number	ANC1
women assessed by		4 years	Number	ANC1
CD4	25-4	9 years	Number	ANC1
	50+	years	Number	ANC1
AN32. HIV+ pregnant	Belo	w 15 years		
women initiated on ART for eMTCT at		9 years		
Any visit irrespective		4 years		
of when tested HIV+				
(TRR, TRR+ and HIV+ not yet started	25-4	9 years 		
ART(TRR√ & TRRK))	50+	years		
	Total	(TRK + TRRK)		
AN33. Pregnant		Below 15 years		
Women who knew status before 1st ANC	HIV+ (TRRK)	15-19 years		
		20-24 years		
		25-49 years		
	=	50+ years		
		Total ART-K during the month		
	low 15 years	Viral Load Samples collected during the month		
	/ 15	Viral Load results		
		Returned during the month		
	Be	Viral Load		
		Suppressed during the month		
		Total ART-K		
		during the month		
		Viral Load		
AN34.HIV+ pregnant	ars	Samples collected during the month		
women already on ART before 1st ANC	15-19 years	Viral Load results		
(ART-K)	5-1	Returned during		
	_	the month		
		Viral Load Suppressed		
		during the month		
		Total ART-K		
		during the month Viral Load		-
	ars	Samples collected		
	20-24 years	during the month		
)-24	Viral Load results Returned during		
	20	the month	ļ	
		Viral Load Suppressed		
		during the month		

THLY RE	POR	RT		Page 1	1 J	TRY OF HEALTH
2.1 ANTEN	ATAL (Cont	inued)			NUMBER
			Total A	Total ART-K during the month		
				ral Load Samples llected during the month		
AN34.HIV+		25-49 years		oad results Ret the month	urned	
pregnant women alrea on ART befo		25	Viral I	oad Suppressorth	ed	
1st ANC (A	RT-K)		Total A	RT-K during the	month	
(Continued)		50+ years		oad Samples ted during the n	nonth	
		<u>`</u>		oad results		
		20		ned during the r Load Suppress		
				the month		
AN35. Pregn			Total	(TR+ &TRR+)		
pregnancy	u iaiei	111	HIV+	(TRR+)		
AN36. HIV+ p the un born in	oregna nfants f	nt wo	men give 1st tim	en ARV prophyl e in ANC	axis for	
AN37. Pregn		Tota	l			
women given self-testing kits for		s returne	ed HIV+			
their male northers			s returne	ed HIV negative)	
AN38: Male pa		Tota	l tested	(TR & TRR)		
results in eMT		HIV-	+ (TRR).			
AN39. Male pa with a known s		Tota	I (TRK 8	TRRK)		
at their first visi couple in ANC	t as a	HIV-	'+ (TRRK)			
	Male p	artne	ers initiat	ed on ART in the	ne ANC	
AN41. Numb	er of di	score	dant cou	ple identified in	ANC	
AN42. Pregnant	Mater	nal N	utrition	Total		
women	Couns	sellin	9	HIV+		
who received	Infant	Feeding		Total		
Counselling		9	HIV+			
2.2 MATERN	IITY		'			NUMBER
MA01: Admis	ssions					
MA02: Refer	rals to		Total			
maternity uni			From community services			

MAGA A L : :				
MA01: Admissic				
MA02: Referrals to maternity unit Total From com		Total		
		rom community services		
MA03: Maternity referrals out				
MA04:			Below 15 years	
	MA04a. Total		15-19 years	
			20-24 years	
			25-49 years	
			50+ years	
Deliveries in unit	MA04b. Live births		Total	
unit			< 2.5 Kg	
	MA04c. Fresh still birth		Total	
			< 2.5 Kg	
	MA04d. Macerated still		Total	
	birth	icu silli	< 2.5 Kg	
		Į.	Print Version Sente	mher 2010





2.2 MATERNITY (continue	ed)			
,				NUMBER
		Total		
MA05. Pre-Term births		Alive	/	
		< 2.5 l	∧g	
MA06. Born Before Arrival		Alive		
		< 2.5	Kg	
MA07. No. of low birth weig		abies (<2		
initiated on kangaro				
MA08. Live babies at disch				
MA09. No. of Babies born v				
MA10. No. of Babies receiv				
MA11. Newborn deaths (0-	7 da	ys)		
MA12. Neonatal Death 8-28	3 da	ys		
		Below 15	years	
		15-19 yea	ars	
MA13. Maternal deaths		20-24 yea		
		25-49 yea		
		50+ years		
MA14. No. of mothers who				
initiated breastfeeding withi	n	Total		
the 1st hour after delivery		No. HIV +		
MA15. Women tested for HI\		Total (TR & TRR)		
labour 1st time this Pregnand	cy 	HIV+ (TRR)		
MA16. Women re-tested for	r	Total (TR+ & TRR+)		
HIV in labour		HIV+ (TRR+)		
MA17. HIV+ women initiatir	ng A	RT in mat	ernity	
MA18. Male partners receiv	/ed	Total (TR &	TRR)	
HIV test results in the maternity setting		HIV+ (TRR)		
MA19. HIV+ male partners	initia			
the maternity setting				
MA20. Number of discordar in maternity	nt co	ouples ide	ntified	
,	Ma	 iternal	Total	
MAQA Mathana Dagaiyad		tritional	HIV+	
MA21. Mothers Received nutrition Counselling			Total	
3		ant eding		
	 		HIV+	
MA22. Deliveries to HIV+	Tot			
women in unit	Liv	e births		
MA23. HIV Exposed	Tot	al number	·	
infants given ARVs	Number of high-risk infants 12 weeks			
MA24. No. of babies with B				
MA25: No. of Live babies S Resuscitated	ucc	essfully		
MA26. Number received	Ва	by		
PNC check at 6 hours after birth	Mother			

2.2 MATERNITY (Continued)		NUMBER
MA27. Number received PNC	Baby	
within 24 hours after birth	Mother	
	Oxytocin	
MA28. Uterotonics used in management of 3rd stage of labour	Misoprostol	
	Egometrine	

	<u> </u>			
2.3 POSTNATAL	NUMBER			
		Below 15 y	/ears	
PN01.Post Natal Attendances		15-19 year	s	
	Age group	20-24 year	s	
		25-49 year	s	
		50+ years		
Attendances		24 Hours		
	Timing	6 Days		
	Tilling	6 Weeks		
		6 Months		
PN02. Referrals to	Total referr	als		
PNC unit	From comm	nunity servi	ces	
PN03. Breast feeding mothers tested for	Total (TR &	TRR)		
HIV 1st time during Postnatal	HIV+ (TRR))		
PN04.Breastfeeding	Total (TR+	& TRR+)		
mothers re-tested for HIV during Postnatal	TRR+			
	Total HIV+			
PN05. HIV+ women	New Positiv	es (TRR)		
initiating ART in Postnatal	Positive on re-test (TRR+)			
Fostilatai	Positives but			
PN06.HIV+ breastfee	ANC, Labour			
MCH groups				
PN07: Mother-baby p point	airs enrolled a	at Mother-Ba 	by care	
PN08. Male partners received HIV	Total (TR &	Total (TR & TRR)		
test results in the postnatal setting	HIV+ (TRR))		
PN09. HIV+ male par postnatal setting	tners initiated	on ART in th	ie	
PN10.Breast feeding mothers	Total			
given self-testing	Tests return	ed HIV+		
kits for their male partners	Tests return	ned HIV neg	ative	
PN11. Number of dis	cordant coup	les identified	I in PNC	
PN12. Cancer of	Clients scre the Breast	ened for Ca	ancer of	
the breast	Clients with pre-malignant conditions of breast			
PN13. Cancer of	Clients scre the Cervix		ancer of	
the Cervix Clients with pre-maligrounditions of cervix		pre-malign of cervix	ant	
PN14. Lactating mo	PN14. Lactating mothers who received Total			
Nutritional assessm			HIV+	
DN45 D :	Mataria	.4ui4i a.v 1	Total	
PN15. Post- natal mothers	Maternal N	utritional	HIV+	
who received Counselling	lf- (= :	·	Total	
u auncallina	Infant Feeding		HIV+	†

Page	13	Q'
		MINISTRY OF HEALT

2.4 EXPOSED INFANT D SERVICES	IAGNOSIS (EID)	NUMBER			
	Total				
ED01. Exposed Infants Tested for HIV below 18	Within 2 Months				
months of age by 1st	Tested HIV+				
PCR	Tested HIV+ within 2				
ED02. Exposed Infants	months Total				
Tested for HIV by 2nd	Tested HIV+				
PCR ED03. Exposed Infants	Total				
Tested for HIV by 3rd	Tested HIV+				
PCR	Total				
ED04. 1st DNA/PCR	Results returned within 2	1			
results returned	weeks				
	Results given to caregiver				
	Total				
ED05. 2nd DNA/PCR results returned	Results returned within 2 weeks				
rodano rotarrioa	Results given to caregiver				
FD06, DNA/PCR 6	Total				
weeks after cessation	Results returned within 2				
of breastfeeding results returned	weeks	+			
	Results given to caregiver				
ED07.HIV exposed infants of first time at mother baby care	given ARV propnylaxis for the e point	9			
ED08. Number of HIV+	Total				
infants from EID enrolled on ART	Within 2 Months				
ED09. HIV exposed	Total				
started on CPT	Within 2 Months				
2.4.1 OUTCOMES OF HI	V EXPOSED INFANTS	NUMBER			
REGISTERED 24 MONTI OE01.Total number of HEIs					
OE02. HEIs that initiated /		•			
eMTCT between 0-6 weel	ks in the cohort				
OE03. HEIs that received					
	weeks (High risk infants) in the cohort				
weeks (High risk infants) i	n the cohort CTX prophylaxis at the				
weeks (High risk infants) i OE04. HEIs that received age within 2 months in the	CTX prophylaxis at the cohort				
weeks (High risk infants) i OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s	CTX prophylaxis at the cohort				
weeks (High risk infants) i OE04. HEIs that received age within 2 months in the	CTX prophylaxis at the cohort t DNA/PCR done within				
weeks (High risk infants) i OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age	CTX prophylaxis at the cohort t DNA/PCR done within d DNA/PCR at 9 months				
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months VPCR done at 6 weeks				
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfe OE08. Number of HIV exp	CTX prophylaxis at the e cohort t DNA/PCR done within d DNA/PCR at 9 months VPCR done at 6 weeks edding posed infants exclusively				
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfe OE08. Number of HIV expreastfed for the first 6 co	CTX prophylaxis at the e cohort t DNA/PCR done within d DNA/PCR at 9 months VPCR done at 6 weeks edding posed infants exclusively				
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfer OE08. Number of HIV expreastfed for the first 6 counter the open of the counter of the coun	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months d/PCR done at 6 weeks edding cosed infants exclusively mpleted months during cosed infants who were				
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfe OE08. Number of HIV expreastfed for the first 6 counter the counter of the co	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months d/PCR done at 6 weeks deding cosed infants exclusively mpleted months during cosed infants who were up-to 1 year				
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfer OE08. Number of HIV expreastfed for the first 6 counter the open of the counter of the coun	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months d/PCR done at 6 weeks deding cosed infants exclusively mpleted months during cosed infants who were up-to 1 year	NUMBER			
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfe OE08. Number of HIV expreastfed for the first 6 co the reporting period OE09. Number of HIV expreported to be breastfed up 2.4.2 FINAL TEST RESU 24 months. OE10.Number of HIV expressions of the content of the con	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months d/PCR done at 6 weeks leding loosed infants exclusively mpleted months during loosed infants who were lep-to 1 year LTS –HEI Outcomes at loosed Total	NUMBER			
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfe OE08. Number of HIV expreastfed for the first 6 co the reporting period OE09. Number of HIV expreported to be breastfed up 2.4.2 FINAL TEST RESU 24 months. OE10.Number of HIV expinfants tested HIV positive	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months d/PCR done at 6 weeks edding cosed infants exclusively mpleted months during cosed infants who were up-to 1 year LTS -HEI Outcomes at cosed con	NUMBER			
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfe OE08. Number of HIV expreastfed for the first 6 co the reporting period OE09. Number of HIV expreported to be breastfed up. 2.4.2 FINAL TEST RESU 24 months. OE10.Number of HIV expinfants tested HIV positive any DNA/PCR or rapid testo DE11.Number of HIV exponents of HIV expinfants tested HIV positive any DNA/PCR or rapid testo DE11.Number of HIV expinfants of HIV expinfants tested HIV positive any DNA/PCR or rapid testo DE11.Number of HIV expinfants of HIV expinfants tested HIV positive any DNA/PCR or rapid testo DE11.Number of HIV expinfants	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months VPCR done at 6 weeks teding toosed infants exclusively mpleted months during toosed infants who were toosed infants who w	NUMBER			
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfe OE08. Number of HIV expreastfed for the first 6 co the reporting period OE09. Number of HIV expreported to be breastfed under the context of the context	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months VPCR done at 6 weeks reding rosed infants exclusively mpleted months during rosed infants who were rep-to 1 year LTS -HEI Outcomes at Total rosed infants who died rosed infants who died rosed infants who died	NUMBER			
weeks (High risk infants) i OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfe OE08. Number of HIV exp breastfed for the first 6 co the reporting period OE09. Number of HIV exp reported to be breastfed u 2.4.2 FINAL TEST RESU 24 months. OE10.Number of HIV exp infants tested HIV positive any DNA/PCR or rapid tes OE11.Number of HIV exp before 18 months of age OE12.Number of HIV exp out before 18 months of a	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months d/PCR done at 6 weeks reding rosed infants exclusively mpleted months during rosed infants who were rep-to 1 year LTS -HEI Outcomes at rosed red infants who died red infants who died rosed infants who died rosed infants who died	NUMBER			
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfe OE08. Number of HIV expressived for the first 6 counter the reporting period OE09. Number of HIV expreported to be breastfed uz.4.2 FINAL TEST RESU 24 months. OE10.Number of HIV exprinfants tested HIV positive any DNA/PCR or rapid testo OE11.Number of HIV expreported to be serviced any DNA/PCR or rapid testo OE11.Number of HIV expreported 18 months of age OE12.Number of HIV expreported 18 months of a OE13.Number of HIV expreported 18 months of a OE13.Number of HIV expreported the positive and the po	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months d/PCR done at 6 weeks reding rosed infants exclusively mpleted months during rosed infants who were rip-to 1 year LTS -HEI Outcomes at Total rip on at Initiated on ART rosed infants who died rosed infants who died rosed infants transferred ge rosed infants were lost to so of age	NUMBER			
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfe OE08. Number of HIV exp breastfed for the first 6 co the reporting period OE09. Number of HIV expreported to be breastfed under the test of the reporting period OE09. Number of HIV expreported to be breastfed under the test of the reporting period OE10. Number of HIV expreported to be breastfed under the test of the reporting period of the test of the test of the reporting period of the test	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months VPCR done at 6 weeks reding rosed infants exclusively mpleted months during rosed infants who were rip-to 1 year LTS -HEI Outcomes at Total rosed infants who died rosed infants transferred ge rosed infants who died rosed infants who died	NUMBER			
weeks (High risk infants) in OE04. HEIs that received age within 2 months in the OE05. HEIs that had a 1s 2 months OE06. HEIs that had a 2n of age OE07. HEIs that had DNA after cessation of breastfe OE08. Number of HIV expressived for the first 6 counter the reporting period OE09. Number of HIV expreported to be breastfed uz.4.2 FINAL TEST RESU 24 months. OE10.Number of HIV exprinfants tested HIV positive any DNA/PCR or rapid testo OE11.Number of HIV expreported to be serviced any DNA/PCR or rapid testo OE11.Number of HIV expreported 18 months of age OE12.Number of HIV expreported 18 months of a OE13.Number of HIV expreported 18 months of a OE13.Number of HIV expreported the positive and the po	CTX prophylaxis at the ecohort t DNA/PCR done within d DNA/PCR at 9 months VPCR done at 6 weeks reding rosed infants exclusively mpleted months during rosed infants who were rip-to 1 year LTS -HEI Outcomes at Total rosed infants who died	NUMBER			

2.5 EARLY RETENTION MONITORING FOR EMTCT WOMEN				
	NUMBER	NET CURRENT COHORT*		
ER01. EMTCT mothers known to be active on ART treatment 1 month after ART initiation				
ER02. EMTCT mothers known to be active on ART treatment 2 months after ART initiation				
ER03. EMTCT mothers known to be active on ART treatment 3 months after ART initiation				
*Net current Cohort=Original Cohort + Transfer In – Transfer Out				

2.6 FAMILY PLANNING	NEW USERS	REVISITS	
	Below 15 years		
FP01.Oral: Lo-Femenal	15-19 years		
	20-24 years		
	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years	1	İ
FP02. Oral: Microgynon	20-24 years		
iviiorogyriori	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP03. Oral: Ovrette or another POP	20-24 years		
	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP04. Oral: Levonogesteral	20-24 years		
Levenogestera	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP05. Oral: Others	20-24 years		
	25-49 years		
	50+ years		
	Below 15 years		
FP06. Injectable	15-19 years		
DMPA(IM e.g Depo)3	20-24 years		
months	25-49 years		
	50+ years		
	Below 15 years		
FP07.Injectable	15-19 years		
DMPA(ŚC e.g Sayana	20-24 years		
press) 3 months	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP08. Injection 2 months	20-24 years		
	25-49 years		
	50+ years		



2.6 FAMILY PLANNING I	METHODS	NEW USERS	REVISITS
	Below 15 years		
FP09. Injection 1	15-19 years		
	20-24 years		
monui	25-49 years		
	50+ years		
	Below 15 years		
ED40.0 : 1.1	15-19 years		
FP10. 3 year implant (e.g. implananon NXT,	20-24 years		
Levo plant)	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP11. 4 year implant	20-24 years		
(e.g. Sino plant)	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP12. 5 year implant	20-24 years		
(e.g. Jadella)	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP13. IUD-Copper-T	20-24 years		
	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP14. IUD-Hormonal	20-24 years		
	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP15. FAM-SDM method	20-24 years		
method	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP16. FAM-LAM	20-24 years		
	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP17. FAM-Two Days Method	20-24 years		
IVICII IUU	25-49 years		
	50+ years		
	Below 15 years		
FD40 F	15-19 years		
FP18. Emergency Contraceptive Pills	20-24 years		
users	25-49 years		
	-		
	50+ years		

2.6 FAMILY PLANNING METHODS		NEW USERS	REVISITS
	Below 15 years		
FP19. Female	15-19 years		
condoms	20-24 years		
	25-49 years		
	50+ years		
	Below 15 years		
	15-19 years		
FP20. Male condoms	20-24 years		
	25-49 years		
	50+ years		

2.6.1 CONTRACEPTIVES DISPENSED	NO. DISP. AT UNIT	NO. DISP. IN OUTREACH	NO. DISP. BY CBDs	NO. DISP. BY PHARMACIES/ DRUG SHOPS
CT01. Oral: Lo-Femenal (cycles)				
CT02. Oral: Microgynon (cycles)				
CT03. Oral: Ovrette or other POP (cycles)				
CT04. Oral: Levonogesteral (cycles)				
CT05. Oral: Emergency contraceptives				
CT06. Oral: Others (cycles)				
CT07. Female condoms (pieces)				
CT08. Male condoms (pieces)				
CT09: Injectable 3 months IM (doses)				
CT10. Injectable 3 months SC (doses)				
CT11. Injectable 2 months (doses)				
CT12. Injectable 1 month (doses)				
CT13. FAM-SDM (Cycle beads) (pieces)				
CT14. IUDs-Copper T				
CT15. IUDs –Hormonal				
CT16. 3 year implant (e.g impalanon NXT, Levo plant)				
CT17. 4 year implant (e.g Sino plant)				
CT18. 5 year implant (e.g Jadella)				

2.6.2 MINOR OPERATIONS IN FAMILY PLANNING										
		Below 15 years								
PFH01. No of Mothers who received family		15-19 years								
	Timing	20-24 years								
		25-49 years								
		50+ years								
planning in Postpartum by		Below 15 years								
F OStpartum by		15-19 years								
	Method	20-24 years								
		25-49 years								
		50+ years								
MF03-Implant r	emovals									
MF04-IUD remo										





2.6.3 INTEGRATED SERVICES	IN FAMILY PLANNIN	IG
Data Element		NUMBER
FH01. Number HIV+ FP Users		
FH02. Number of FP Users screen		
FH03. STI screening in	Total screened	
Family planning	Positive	

2.6.4 POST PER	RTERM FAI	MILY PLANNING	
		Less Than 48 hours	
PFH01. No of		48hrs to 3 weeks	
	Timing	4weeks to 5weeks	
		6 weeks to 5 months	
Mothers who received family		6 months to 12 months	
planning in Postpartum by		Oral formulation	
F 05tpartum by		Injectable	
	Method	implants	
		IUDs	
		Sterilization	

		6 – 11	Months	12 – 59	Months	5 – 14 Years		
		Male	Female	Male	Female	Male	Female	
CH01- Vit A supplement	Static							
(1st dose)	Outreach							
	In school							
CH02- Vit A supplement	Static							
(2nd dose)	Outreach							
	In school							
CH03- Dewormed (1st dose)	Static							
	Outreach							
	In school							
CH04- Dewormed	Static							
(2nd dose)	Outreach							
	In school							
2.7.1 HPV VACCINATION								
Vaccination of only 10 years OLD girls			Facility (F)		hool (S)	Community (C)		
VP01. HPV1-Dose 1								
VP02.HPV2-Dose 2								

Doses	Pregnant w	omen	Non-pregna	Non-pregnant women					
	Static	Outreach	Static	Outreach	Immunization in School				
TD01. Td1-Dose 1									
TD02. Td2-Dose 2									
TD03. Td3-Dose 3									
TD04. Td4-Dose 4									
TD05. Td5-Dose 5									



2.7.3 CHILD IMMUNISATION									
Doses	Un	der 1	1-4	Years	5 – 14 Years				
Doses	Static	Outreach	Static	Outreach	Static	Outreach			
CL01. BCG									
CL02. Protection At Birth for Td(PAB)									
CL03. Polio 0									
CL04. Polio 1									
CL05. Polio 2									
CL06. Polio 3									
CL07. IPV									
CL08. DPT-HepB+Hib 1									
CL09. DPT-HepB+Hib 2									
CL10. DPT-HepB+Hib 3									
CL11. PCV 1									
CL12. PCV 2									
CL13. PCV 3									
CL14. Rotavirus 1 Vaccine									
CL15. Rotavirus 2 Vaccine									
CL16. Measles (MR1)									
CL17. Measles 2 (MR2)									
CL18. Fully immunized by 1 year									
CL19. Number received LLIN									

2.7.4 VACCINE AVAILABILITY AND V	NASTAGE				
	Open Balance	Received	Closing	Doses v	vasted
Antigen	(A)	(B)	Balance (C)	Doses in Closed Vials (CV)	Doses in Open Vials (OV)
WT01. BCG					
WT02. Polio (OPV)					
WT03. IPV					
WT04. DPT+HepB+Hib					
WT05. PCV					
WT06. Rotavirus					
WT07. Measles					
WT08. Td					
WT09. HPV					
WT10. Yellow Fever					
2.7.5 COLD CHAIN MONITORING					
CC01. Number of high temperature ala	arms				
CC02. Number of low temperature ala	rms				
CC03. Number of cold chain refrigerat	ors available				
CC04. Number of cold chain refrigerat	ors that are function	nal			



2.7.6 EPI/EID/PMTCT Integration		TOTAL							
PI01. Number of Infants screened for HIV-exposure at DPT1, 2, 3 and Measles immunization	during month								
PI02. Number of HIV-exposed infants identified at immunisation during the month									
PI03. Number of HIV-exposed infants tested during immunisation during the month									
DIO4. No wash on of the coefficient washing to stand for LIN/ for the first time at improve institute	Total (TR & TRR)								
PI04. Number of breastfeeding women tested for HIV for the first time at immunization	TRR								
DIOS Number of broadfeeding warmen with a known LIIV status at immunitation	Total (TRK & TRRK)								
PI05. Number of breastfeeding women with a known HIV status at immunization	TRRK								
DICC Number of hypothesiding vicence to tested for LINV at increasing time	Total (TR+ & TRR+)								
PI06. Number of breastfeeding women re-tested for HIV at immunization	TRR+								
PI07. Number of HIV+ breastfeeding women identified at immunization initiating ART									

3.0 HEPATITIS									
		<10)yrs	10-1	9yrs	20-5	9yrs	60+ y	ears
		М	F	М	F	М	F	М	F
HB01. Number of clients tested for HepE	3								
HB02. Number tested negative for HepB									
	1st Dose (New)								
HB03. Number tested negative for HepB and Vaccinated	2nd Dose(Revisit)								
·	3rd Dose(Revisit)								
HB03. Number tested negative for HepB and Vaccinated 2nd Dose(Revisit)									
HB05. Number tested positive for HepB	and enrolled for treatment								
HB06. Number tested positive for HepB and r	not enrolled into care and treatment								
HB07. Number of persons assessed for (viral load suppression)	HepB treatment effectiveness								
HB08. Number of persons with HepB effective	e treatment (viral load suppression)								
HB09. Number of pregnant women tested for	or HepB (Subset of row 1)								
HB10. Number of pregnant women tested p	ositive for HepB (Subset of row 4)								
HB11. Number of pregnant women teste initiated on HepB treatment (Subset of re	d positive for HepB and ow 5)								
HB12. Number tested for HepC									
HB13. Number tested positive for HepC	(Anti-HCV)								
HB14. Number confirmed positive for He	pC (HCV RNA)								
HB15. Number tested positive for HCV F	RNA and enrolled for treatment								
HB16. Number of persons assessed for	HepC Sustained Viral response								

Page 18



4.0 HIV/AIDS TESTING SERVICES (HTS)

		, ,	indivi	ber of duals w 1yr	indivi	ber of duals - 4	indivi	ber of duals - 9	indivi	Number of individuals 10 – 14		Number of individuals 15 - 19		ber of duals - 24	indivi	ber of iduals - 29	indivi	ber of duals - 34	indiv	ber of duals – 39	indivi	ber of duals – 45	indiv	ber of iduals – 49	indivi	ber of iduals 0+
			М	F	М	F	М	F	M	F	М	F	М	F	М	F	M	F	М	F	М	F	М	F	М	F
		Tested for HIV																								
1	Ward/IPD	New HIV positive																								
		Linked to HIV care																								
		Tested for HIV																								
	OPD	New HIV positive																								
		Linked to HIV care																								
		Tested for HIV																								
	ART Clinic	New HIV positive																								
		Linked to HIV care																								
		Tested for HIV																								
	TB Clinic	New HIV positive																								
<u></u>		Linked to HIV care																								
HT01. Number of individuals (by Entry Point for Health facility testing)		Tested for HIV																								
uals y te	Nutrition Unit	New HIV positive																								
livid acilit	01111	Linked to HIV care																								
finc Ith f		Tested for HIV									ĺ															
er o Hea	STI Clinic	New HIV positive																								
umb for		Linked to HIV care																								
z in	Young	Tested for HIV																								
IT try F	Child	New HIV positive																								
Į.	Clinic	Linked to HIV care																								
(q)		Tested for HIV																								
	ANC	New HIV positive																								
		Linked to HIV care																								
		Tested for HIV																								
	Maternity	New HIV positive																								
		Linked to HIV care																				ĺ				
		Tested for HIV																								
	PNC	New HIV positive																								
		Linked to HIV care																								
		Tested for HIV																								
	Family	New HIV positive																								
	Planning	Linked to HIV care																								



			Numb indivi Belov	duals	indivi	per of duals - 4	indivi	per of duals - 9	Numb indivi	duals		per of duals - 19	Numb indivi 20 -	duals		ber of duals - 29	Numb indivi	duals		per of duals - 39	Numb indivi 40 -	duals	Numl indivi 46 -	duals	Numk individ	duals
			M	F	М	F	M	F	М	F	M	F	M	F	М	F	М	F	М	F	М	F	M	F	M	F
ıţ		Tested for HIV																								
HT01. Number of individuals (by Entry Point for Health facility testing)	SMC	New HIV positive																								
divic alth i		Linked to HIV care																								
Here (S		Tested for HIV																								
t for	EID	New HIV positive																								
Jum Point te		Linked to HIV care																								
Ity F	Other	Tested for HIV																								
护	Other Facility Based	New HIV positive																								
1 (a)	Points	Linked to HIV care																								
		Tested for HIV																								
٥	Work place	New HIV positive																								
int	pidoc	Linked to HIV care																								
y Po	Home-	Tested for HIV																								
-intr	Based	New HIV positive																								
(by E	Testing	Linked to HIV care																								
ls (Tested for HIV																								
idua	Drop in centre	New HIV positive																								
Jaliv	Centre	Linked to HIV care																								
Ofi		Tested for HIV																								
her	Hotspots	New HIV positive																								
Nun		Linked to HIV care																								
HT02 Number of individuals (by Entry Point for Community testing)	Othor	Tested for HIV																								
토	Other Community	New HIV positive																								
	Testing	Linked to HIV care																								
ЦТО2	Total	Tested for HIV																								
numbe	iotai <u> </u>	New HIV positive																								
Individ	uals	Linked to HIV care																								
		Tested for HIV																								
ir of Child	Health Facility	New HIV positive																								
HT04. Number of individuals (by PITC Testing approach)	Facility	Linked to HIV care																								\Box
. Nt uals ng ap		Tested for HIV																							\Box	
HT04 divid estir	Community	New HIV positive																								
		Linked to HIV care																							\Box	



			indivi	ber of duals w 1yr	Numl indivi 1 -	duals	indivi	ber of duals - 9	Numl indivi 10 -		Numl indivi 15 -	duals	Numl indivi 20 -	duals	Numl indivi 25	duals	Numl indivi 30 -	duals	indivi	ber of duals – 39	Numl indivi 40 -		indivi	ber of duals - 49	Numk indivi	per of duals
			М	F	М	F	M	F	M	F	М	F	М	F	M	F	М	F	М	F	М	F	M	F	М	F
CT		Tested for HIV																								
ach	Health Facility	New HIV positive																								
HT05. Number of individuals (by CICT/VICT Testing approach	,	Linked to HIV care																								
als(b) ting a		Tested for HIV																								
HTC	Community	New HIV positive																								
in		Linked to HIV care																								
		ndividuals who received																								
	t results	ndividuals tested for the first	-																		-					-
time ev	er																									
	otal Numbe sitive (New	r of Individuals who tested																								
	umber of ne	udv.																			<u> </u>					
diagnos	ed HIV posi	tive Long-term intection																								
for rece	als with a te	esult Recent infection																								
HT10. F	IV positive	individuals with																								
	ptive TB	ndividuals tested more than	_					 																 		
	the last 12																									
HT12. N	Number of in	ndividuals who were																								
HT13. N	Number of in	sted together as a Couple dividuals who were Tested	-		<u> </u>	<u> </u>		<u> </u>											<u> </u>					<u> </u>		
and Re	ceived result	s together as a Couple	-	_													_									
		tested as Couples																								
		individual with Discordant																								
results	wno tested	as Couples	_																							
HT16. lı	ndividuals co	unselled and tested for PEP																								
		viduals tested as Special																								
Categori	ies	Tested for HIV																								
SE	Prisone																			-				<u> </u>		
l sidu	II IISOITE	Linked to HIV Care													-					-						-
ndiv																				\vdash						-
Prisoners Tested HIV Posit Linked to HIV C Tested for HIV Tested HIV Posit Linked to HIV C Tested HIV Posit Linked to HIV C Tested HIV Posit Linked to HIV C Tested For HIV Tested HIV Posit Tested HIV Posit Tested HIV Posit		Mho	\vdash																	-				<u> </u>		
		rugs	\vdash				-								-					\vdash	-					-
Nur		Tested for HIV																	 							
1.8	Uniform	od -																								
=	men	lested HIV Positive																								
		Linked to HIV Care																		<u> </u>						



				ber of duals w 1yr	Numl indivi 1 -	duals	indivi	per of duals - 9	indivi	ber of duals - 14		ber of duals - 19	indivi	ber of duals - 24	indivi	ber of iduals - 29		per of duals - 34	indivi	ber of duals - 39	indivi	ber of iduals – 45	indivi	ber of iduals – 49	indivi	ber of iduals 0+
			М	F	М	F	М	F	М	F	М	F	M	F	М	F	М	F	М	F	М	F	М	F	М	F
		Tested for HIV																								
	Migrant Workers	Tested HIV Positive																								
		Linked to HIV Care																								
		Tested for HIV																								
	Truckers	Tested HIV Positive																								
		Linked to HIV Care																								
		Tested for HIV																								
	Fisher Folk	Tested HIV Positive																								
		Linked to HIV Care																								
		Tested for HIV																								
<u>s</u>	Refuges	Tested HIV Positive																								
vidua		Linked to HIV Care																								
HT18. Number of individuals		Tested for HIV																								\Box
oer of	Pregnant women	Tested HIV Positive																								
dumk		Linked to HIV Care																								
18.		Tested for HIV																								\Box
도		Tested HIV Positive																								\Box
	women Adolescent Girls and	Linked to HIV Care																								
		Tested for HIV																								
		Tested HIV Positive																								\Box
	Young Women (AGYW)	Linked to HIV Care																								
	Daniel with	Tested for HIV																								
	People with Disabilities (PWD) Others	Tested HIV Positive																								
		Linked to HIV Care																								
		Tested for HIV																								
		Tested HIV Positive																								
		Linked to HIV Care																								



			indivi	per of duals w 1yr	indivi	ber of iduals – 4	Numl indivi 5 -		Numb individud 10 -	duals	Numb indivi	duals	Numb individud 20 –	duals	Numb indivi 25 -	duals	Numk indivi 30 -	duals	indivi	ber of duals - 39	Numk indivi 40 -	duals	Numl indivi 46 -	duals	Numk individed	per of duals
			M	F	M	F	M	F	M	F	M	F	М	F	M	F	M	F	М	F	M	F	M	F	M	F
	HT19. Number of partners	Elicited																								
	or partners	Notified																								
	HT20. Number	Total																								
APN	of partners tested	HIV Positive																								
	HT21. Number	Already in HIV care																								
	of HIV-positive partners	Linked to HIV care/ ART																								
	HT22. Number of HIV Self-Test	Directly Assisted																								
LINVOT	kits distributed by model	Unassisted																								
HIVST	HT23. Number report a Positive	of individuals who HIV Self-Test																								
	HT24. Number confirmed positing National algorith	of individuals with ve results with the m																								

E 12 5	

5.0 SAFE MALE CIRCUMCISION	(SMC)														COLUMN TO COLUMN
Category	Age Gr	oup	0-60 days	>2mth- <1yr	1 – 9 Yrs	10 – 14 Yrs	15 – 19 Yrs	20 – 24 Yrs	25 – 29 Yrs	30 – 34 Yrs	35 – 39 Yrs	40 – 44 Yrs	45-49 Yrs	50+ Yrs	Total
	+VE														
SM01. Number of Males	-VE														
Counselled and Tested for HIV at	INC														
SMC site	Known +V	E													
	Not Tested	1													
SM02. Number of Males	F1114	sc													
Circumcised (by Age Group-	Facility	DC													
Years) and Technique (SC - Surgical SMC, DC - Device-	0	sc													
Based SMC)	Outreach	DC													
						Taabaiaaa					Fac	ility		Outreach	1
						Technique					sc	DC	sc		DC
SM04. Number of males Circumci	iaad wha Ba	turned t	for Follow Un			Within 48 h	ours(0-48)								
SIMO4. Number of males circumc	iseu wilo Re	turrieu	ioi Follow Op			Within 7 da	ys (>0-7)								
						Within 14 d	ays (>0-14)								
						Beyond 14	days								
SM05. Number of males Circumci	ised who Ex	perienc	ed one or mo	re Adverse	Events	Moderate									
(Report only Moderate or Severe	AEs)					Severe									
											NUMBER				
SM06. Number of circumcised ma	aloo with Adv	roroo Ev	vonto			Managed by	y the site								
		/erse E\	rents			Referred									
SM07. Number of clients who rec	eived Td					First dose (
						Second dos	se (Td2)								

Page 24



6.0 ESSENTIAL MEDICINES AND HEALTH SUPPLIES

6.1 STOCK STATUS (Out of stock means that there was NONE left in your health unit STORE)

Note: The primary data sources for this sub-section are the Stock books and Stock Cards

SN.	NAME OF DRUG ITEM	UNIT	Quantity Consumed (units)	Days out of stock	Stock on hand	Quantity expired
SS01	Artemether/Lumefantrine 20/120 mg	Tablet				
SS02	Depot medroxy progesterone acetate (DMPA)	Injectable				
SS03	Amoxicillin 250 mg capsule	Capsule				
SS04	Sulfadoxine/ Pyrimethamine tablet	Tablet				
SS05	ORS Sachets with zinc tablet	Packet				
SS06	Measles Vaccine	Vial				
SS07	Determine HIV 1 & 2 screening test	Tests				
SS08	Stat -pack HIV Confirmatory rapid tests, tests	Tests				
SS09	SD Bioline test Tie-Breaker	Tests				
SS10	CD4 reagent	Tests				
SS11	Malaria Rapid Diagnostic tests	Tests				
SS12	GeneXpert Cartridges	Cartridges				
SS13	Therapeutic milk F75 (75Kcal/100ml)	Packet				
SS14	Oral Liquid Morphine 5ml/ml	Bottle of 500 ml				
SS15	Ready to use Therapeutic feeds (RUTF)	Sacket				
SS16	TDF/3TC/EFV 300mg/300mg/(600mg or 400mg)tablet	Pack of 30				
SS17	AZT/3TC/NVP 300mg/150mg/200mg	Pack of 60				
SS18	Atazanavir /ritonavir (ATV/r) 300/100mg tablet	Pack of 30				
SS19	Tenofovir/Lamivudine (TDF/3TC) 300mg/300mg	Pack of 30				
SS20	TDF/3TC/DTG 300mg/300mg/50mg(TLD)	Pack of 30				
SS21	TLE 300mg/300mg/400mg	Pack of 90				
SS22	Abacavir/Lamivudine (ABC/3TC) 120mg/60mg (Paediatric)	Pack of 30				
SS23	Lopinavir 40mg/ritonavir 10mg pellets in capsules	Pack of 120				
SS24	Cotrimoxazole 960mg tablet	Pack of 1000				
SS25	(RHZE) blister strip 150/75/400/275 mg	28 tablets				
SS26	Blood 450 ml	Unit				
SS27	RHZ Blister 75mg/50mg/150mg	28 tablets				
SS28	Misoprostol 200mcg Tablet**	Tablet				
SS29	Amoxicillin dispersible 250mg tablet.	Tablet				
SS30	Ceftriaxone 1g Injection	Vial				
SS31	Oxytocin Injection	Ampoule				
SS32	Chlorhexidine Digluconate Gel 7.1% (equivalent to 4% chlorhexidine)	Tube				
SS33	Mama Kit**	Kit				
SS34	Bendroflumethiazide (Aprinox) 5mg	Tablet			1	
SS35	Artesunate 60mg	Injection				
SS36	Nifedipine tablets 20mg tablet	Tablet			1	
SS37	Captopril 25mg tablet	Tablet				
SS38	Metformin 500mg	Tablet	1	1		1
SS39	Glibenclamide 5mg tablet	Tablet	<u> </u>			
SS40	Insulin short-acting	Vial	1			
SS41	Cardiac Aspirin 75/80 mg	Tablet				



н	WIS 10	05: H	IEALIH UN	11 0011	PAHEN	I MON	11	ILY RI	EPO	RI		- 1	age	25	STRY OF HEALTH
6.2 A	DD THE	GENEF	RIC NAME OF DRU	JGS, VACCI	NES, CONT	RACEPTIV	ES	OR SUPI	PLIES	THA	HAVE E	XPIRED	DURI	NG THE MO	ONTH:
NO.	ITEM CODE	N	IAME OF DRUG IT	EM	Quanti	ity NO	Э.	ITEM CODE	١	NAME	OF DRU	G ITEM			Quantity
1						6	ヿ								
2						7	ヿ								
3						8	T							ĺ	
4						9	T							ĺ	
5						10	T							ĺ	
7.0 O	UTREAC	НАСТ	IVITIES		•					N	umber Pl	anned	I	Number Co	nducted
OH0 ²	I. EPI Ou	treache	s			,									
OH02	2. HCT O	utreach	es												
OH03	3. Environ	mental	Health Visits												
OH04	I. Health	Educati	on/Promotion Outre	eaches											
OH5.	Maternal	Deaths	s Audited/Reviewed	d (communit	ty Verbal aut	topsy)									
OH06	3.Perinata	al Death	s Audited												
			l services outreach		C, PNC, ASF	RH, ADH, Ca	аСх	screening	g,						
OH08	3. Numbe	r of sur	gical and Treatmen	t camps (e.g	յ, Fistula rep	air, Gynaec	olo	gical cam	ps etc))					
OH09	9. School	health (outreaches												
OH10). Total N	umber o	of Births registered	during outre	aches										
OH11	. Other C	outreach	nes			,									
8.0 M	EETING	S								N	umber Pl	anned	ı	Number Co	nducted
MT01	. Genera	al Staff	Meetings												
MT02	2. Quality	Improv	ement (QI) Meeting	js											
MT03	B. Materna	al& Peri	natal Death Review	v committee	Meetings	,									
MT04	. Health I	Unit Ma	nagement Commit	tee/Hospital	Board Meet	ings									
			countability and clie		review mee	etings (Eg.	Bal	azas, Con	nmunit	ty					
MT06	6. Other M	leetings	<u> </u>												
Healt	h Educa	tion at	Health Facility lev	el						N	umber Pl	anned		Number Co	nducted
MT07	′. Health l	Educati	on sessions at Hea	Ith facility											
Adol	escent /v	outh fr	iendly services			,					10-19	Years		20-24	years
										M	ale	Femal	e I	Vlale	Female
			escents who acces	sed adoleso	ent friendly	corner N	ew			_					
	y service					R	evi	sit					\rightarrow		
			RVISION VISITS							N	umber Pl	anned	'	Number Co	nducted
	. From M												_		
⊢—	. From R														
			ocal Government												
			h Sub-District (HSI	0)						_					
SV05	. Other S	upport	Supervisions done												1
LAB	DRATOR	Υ		,											
numl	1. Total per of lab	orator	y client		mber of Spe For tests do		lec	ted at Fa	cility a	and R	eceived f	rom oth	er		
visits	•			Blood	Stool/ Rectal swab	Urine	S	Sputum	CSF		Pus Swab	Gen Swa		Skin Snip	Others
LV01 Outpa (OPD	atient		SC01. Collected (IN)												
LV02 Inpati (IPD)	ent		SC02. Received (OUT)												



10.2 LABORATORY ROUTINE TESTS					
10.2.1 Number of Routine Tests Done in	acility Labo	oratory			
Lab Tests	Number Done	Numbe Positiv	Lab Tests	Number Done	Number Positive
HEMATOLOGY (BLOOD)			SEROLOGY		
HE01. Hb (Non automated)			SR01.VDRL/ RPR		
HE02. CBC			SR02.TPHA		
HE03. Film Comment			SR03.Shigella Dysentery		
HE04. ESR			SR04. Hepatitis B SAgS		
HE05. Bleeding time			SR05. Brucella		
HE06. Prothrombin time			SR06. Pregnancy Test (HCG)		
HE07. Clotting time			SR07. CRAG		1
HE08. Sickle Cell			SR08. Rheumatoid factor		1
HE09. Others			SR09. Hep B Core Ag		
BLOOD TRANSFUSION			SR10. Hep C	1	1
BT01. AHG (Comb's Test)			SR11. Hep A		
BT02. ABO Grouping			 MICROBIOLOGY (CSF, URINE, STOOL,	BLOOD, SPU	TUM, SWABS)
BT03. Rhesus Grouping			MB01. Auramine (FM) for AFBs	,	
BT04. Cross Matching			MB02. ZN for AFBs	1	
IMMUNOLOGY	<u> </u>		MB03. Leishman Stain		1
IG01. CD4 test			MB04. Gram		
IG02. Viral Load Test			 MB05. India Ink		
IG03. Hep B Viral Load			 MB06. Urine Microscopy		
IG04. TB LAM			MB07. Wet Preps	1	1
MOLECULAR	<u> </u>		MB08. Others	1	
		мтв+	CLINICAL CHEMISTRY		
ML01. TB Genexpert (For Genexpert sites only)		RR	Renal Profile		
ML02. Latent TB Infection test			 RP01. Urea		
ML03. TB Lamp Test		+	RP02. Calcium	1	
PARASITOLOGY(Blood)			RP03. Potassium	1	
PS01. Malaria Microscopy		\top	RP04. Sodium	1	
PS02. Malaria RDTs		_	RP05. Creatinine		
PS03. Trypanosoma		1	Liver Profile		_
PS04. Microfilaria		1	LP01. ALT		
PS05. Leishmania		1	LP02. AST		
PS06. Trichinella		1	LP03. Albumin		
PS07. Borrellia		1	LP04. Total Protein		
STOOL MICROSCOPY			Lipid/Thyroid Profile		_
MS01. Entamoeba			LC01. Triglycerides		
MS02. Giardia Lumblia			LC02. Cholesterol		
MS03. Cryptosporidium			LC03. Free T3		
MS04. Isospora			LC04. Free T4		
MS05. Cyclospora			LC05. TSH		
MS06. Strongyloides			Other Clinical Chemistry Tests		
MS07. Shistosoma			 CX01. Alkaline Phosphate		
MS08. Taenia			CX02. Amylase		
MS09. Askaris			CX03. Glucose		
MS10. Hookworm			CX04. Total Bilirubin	+	
MS11. Trichuris			 CX05. Lipase		
		-	CX05. Lipase CX06. AFP		
MS12. Other parasites					
MS13 Total Tests Done for Stool Microscopy	<u> </u>		CX07. Others		

Number Positive

Number Done

Lab Tests (Continued)
CULTURE & SENSITIVITY



14	1.
MÊ	
M	11
20	A STATE OF THE PARTY OF THE PAR
MINISTRY	OF HEALT

CS01. Blood																	
CS02. Urine																	
CS03. Stool																	
CS04. Genital Swabs																	
CS05. Sputum																	
10.3 SUMMARY OF HI	V TES	TS BY PU	JRPOS	E													
Category		нст	eMTC		linical ignosis	SN		Test Veri cati	ifi-	Recency Testing	IQC	EQA	Total	clu	con- isive sults	Repeat Testers	
HP01. Determine																	
HP02. Statpak																	
HP03. SD Bioline]	
HP04. HIV Syphilis DU	0]	
HP05. Oraquick (Self Te	esting)			Ī												[
10.4 REFERRAL TEST							•										
10.4.1 Volume of Sam	ple Ref	ferred			- 1	Na a											No. of
Type of Test		No. of Specime Referred	en Tu		round	No. of Pendi Resul Feedb	ng ts/		Ту	pe of Test			No. of Specimer Referred	1	Avera Turn A Time	ge Around	No. of Pending Results/ Feedback
Virology			'						Mi	crobiology	(Contin	ued)		-		·	
VS01. EID									VS	15. Neonat	al tetanı	IS					
VS02. Viral Load for HI	V								VS	16. Plague							
VS03. CD4										17. Isolates							
VS04. Sickle Cell Disea Confirmation	se								VS Fe	19. Viral Havers(VHF)	aemorrh:	agic					
VS05. Histology									vs	20. Animal	Bites						
VS06. Polio/or Acute FI Paralysis									(su	spected ral	oies)						
VS07. Severe Acute Reratory Syndrome/Infecti (SARS/SARI)									sar	21. Suspec mples (EBO lers)							
VS08. TB GeneXpert									vs	22. Hepatit	is B core	Ag					
VS09. DST for Multi Dr									VS	23. Hepatit	is B Vira	l Load					
Resistance TB (MDR T Microbiology	в) ј							+	VS	S24. Hepati	tis C Vira	al load					
VS10. Typhoid Fever					Т				Pa	rasitology							
VS11. Cholera								十	-	25. Hemo p	parasites	, [
VS12. Dysentery								\top	-	26. Intestin							
VS13. Rota Virus								\top	+	27. Tissue							
VS14. Meningitis								\top	To	tals				\dashv			
10.5 Number of Routi	ine Tes	ts that c	ould no	t be	conduc	ted a	t facil	ity a			ed to hu	ıb or oth	ner facility	/			
Routine Test Type										ting tests t							
(specify type test)	Equip		Reage:	nt	Suppli	ies	Pow	er		No testing expertise	Lack	of	Confirm	nator		or QA -testing	Others
RT01. CD4																	
RT02. TB															\top		
RT03. CBC											1				+		
RT04. Chemistry									\dashv		1				\top		
RT05. Microbiology				\neg					\dashv		1				\top		
RT06. HIV screening											†				\top		
RT07. VDRL															\top		
RT08. Haematology									\dashv						\top		
RT09. Parasitology									\dashv		1				\top		
	!																



10.6 AMR SURVEILAN	CE																																									
10.6.1 National Priority	AM	R Oı	rgani	isms	3																																					
									W	но ғ	Prior	ity A	MR	Orga	anisı	ns															Oth	er A	MR	Org	anis	ms						
Organisms		Klebsiella			Escherichia coli			Salmonella spp			Shigella spp			Neisseria			Staphylococcus			Streptococcus			Acinetobacter			Vibrio cholera.			Enterococcus spp.		:	Haemophilus Influenza.			Neisseria meningitides.			Campylobacter.			Others	
NP01. No. of Isolates						_	\vdash	_									_			_				_	\vdash													_				
ANTIBIOTICS	R	I	S	R	I	S	R	1	S	R	1	S	R	I	S	R	I	S	R	I	S	R	I	S	R	ı	S	R	1	S	R	I	S	R	I	S	R	I	S	R	I	S
NP02. Ampicilin							╙	$oxed{oxed}$																					Ш											L		\bigsqcup
NP03. Azithromycin																																										
NP04.Amikacin																																										
NP05.Ceftriaxone																																										
NP06.Ceftazidime																																										
NP07.Cefotaxime																																										
NP08.Cefoxitin																																										
NP09.Cefixime																																										
NP10.Cotrimoxazole																																										
NP11.Ciprofloxacin							Π																																			
NP12.Colistin							Π																																			
NP13.Gentamicin							П																																			
NP14.Imipenem							Π																																			
NP15.Levofloxacin																																										
NP16.Meropenem																																										
NP17.Oxacillin							Т																						П													П
NP18.Penicillin G							Π																																			
NP19.Vancomycin							Т																																			П
NP20. Augmentin							П																																			П
NP21.Chloramphenicol				İ			T	İ			İ							İ				İ			İ						T					İ						
NP22.Clindamycin				ĺ														İ				İ			Ĺ																	
NP23.Erythromycin				İ			Τ				İ							İ				ĺ		İ	İ											İ	ĺ					
NP24.Nalidixic acid																																										
NP25.Nitrofurantoin																																										
NP26.Piperacillin							\top																						\Box		\Box											
NP27.Piperacillin/ Tazobactam																																										
NP28.Tetracycline							\top																						\Box													П

10.7. LABORATORY SPECIMEN REJECTION



e	29	P
_		MINISTRY OF HEAL

			Sample Type								
Reasons for Specimen Rejection			Blood	Stool/ Rectal Swab	Urine	Sputum	Pus Swab	Genital Swab	Skin snip	Others	
RS01. Inadequate specimen volume						ĺ					
RS02. Hemolyzed specimen											
RS03. Specimen without lab request form											
RS04. No test specified on lab request form accompanying specimen											
RS05. Specimen without label or identifier											
RS06. Wrong specimen label						ļ					
RS07. Unclear specimen label				<u> </u>							
RS08. Wrong specimen container											
RS09. Damaged specimen container									ļ		
RS10. Too old specimen									ļ		
RS11. Date of specimen collection not specified									ļ		
RS12. Time of specimen collection not specified				-	<u> </u>						
RS13. Specimen type unacceptable for required test											
RS14. Other reasons				 					ļ		
Total	5								<u> </u>		
Phone No.: Email:				SD use only)							
	Date received									\neg	
	Received by 7th of next month Yes				No	No					
	Checked by (signature)									\dashv	
	Date Entered										
	Name of Data Entrant										
COM											